Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in patients with hypertension and left ventricular hypertrophy? The LIFE study

被引：0
|
作者：
Ibsen, H
Olsen, MH
Wachtell, K
Borch-Johnsen, K
Lindholm, L
Dahlof, B
Snapinn, S
机构：
[1] Glostrup Cty Hosp, Glostrup, Denmark
[2] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[3] Umea Univ, Umea, Sweden
[4] Univ Gothenburg, Gothenburg, Sweden
[5] Merck, W Point, PA USA
来源：
JOURNAL OF HYPERTENSION | 2003年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [31] Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study)
    E Gerdts
    M J Roman
    V Palmieri
    K Wachtell
    G Smith
    M S Nieminen
    B Dahlöf
    R B Devereux
    Journal of Human Hypertension, 2004, 18 : 417 - 422
  • [32] Economic evaluation of losartan compared with atenolol in the treatment of hypertension with left ventricular hypertrophy: A cost-minimization analyisis based on life study
    Chevreul, K
    Durand-Zaleski, I
    Souchet, T
    VALUE IN HEALTH, 2003, 6 (03) : 317 - 318
  • [33] Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
    Devereux, RB
    Dahlöf, B
    Gerdts, E
    Boman, K
    Nieminen, MS
    Papademetriou, V
    Rokkedal, J
    Harris, KE
    Edelman, JM
    Wachtell, K
    CIRCULATION, 2004, 110 (11) : 1456 - 1462
  • [34] Economic evaluation of losartan compared with atenolol in the treatment of hypertension with left ventricular hypertrophy: Cost-minimization analysis based on LIFE study
    Chevreul, K
    Durand-Zaleski, I
    Souchet, T
    VALUE IN HEALTH, 2003, 6 (06) : 666 - 666
  • [35] Losartan versus olmesartan in patients with essential hypertension and concentric left ventricular hypertrophy
    Picca, M.
    Agozzino, F.
    Pelosi, G. C.
    JOURNAL OF HYPERTENSION, 2006, 24 : S24 - S24
  • [36] Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy:: The LIFE study
    Reims, HM
    Oparil, S
    Kjeldsen, SE
    Devereux, RB
    Julius, S
    Brady, WE
    Fyhrquist, F
    Ibsen, H
    Lindholm, LH
    Omvik, P
    Wedel, H
    Beevers, G
    De Faire, U
    Kristianson, K
    Lederballe-Pedersen, O
    Nieminen, MS
    Dahlöf, B
    BLOOD PRESSURE, 2004, 13 (06) : 376 - 384
  • [37] Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy:: The LIFE study
    Reims, HM
    Kjeldsen, SE
    Devereux, RB
    Oparil, S
    Julius, S
    Brady, WE
    Dahlöf, B
    JOURNAL OF HYPERTENSION, 2004, 22 : S246 - S246
  • [38] Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study
    Kjeldsen, Sverre E.
    Devereux, Richard B.
    Hille, Darcy A.
    Lyle, Paulette A.
    Dahlof, Bjorn
    Julius, Stevo
    Edelman, Jonathan M.
    Snapinn, Steven M.
    De Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hans
    Lederballe-Pedersen, Ole
    Lindholm, Lars H.
    Nieminen, Markku S.
    Omvik, Per
    Oparil, Suzanne
    Wedel, Hans
    BLOOD PRESSURE, 2009, 18 (06) : 348 - 361
  • [39] Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy
    Fossum, E
    Olsen, MH
    Hoieggen, A
    Wachtell, K
    Reims, HM
    Ibsen, H
    Julius, S
    Kjeldsen, SE
    JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (06) : 375 - 380
  • [40] Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy
    E Fossum
    M H Olsen
    A Høieggen
    K Wachtell
    H M Reims
    H Ibsen
    S Julius
    S E Kjeldsen
    Journal of Human Hypertension, 2004, 18 : 375 - 380
12345